循证医学与心衰疗.pptVIP

Captopril 0 0.1 0.2 0.3 0.4 0 6 12 18 24 30 36 Months Probability of Event Study DrugDiscontinuation Overall Due to Adverse Events *P 0.05 vs Captopril Valsartan + Captopril * * Valsartan * * * * * Valsartan ? ? Valsartan + Captopril Captopril Hypo- Renal Hyper- Cough Skin Taste Angio- tension Causes kalemia Rash Disturbance edema Adverse Experience Leading to Study Drug Discontinuation * P 0.05 Valsartan vs. Captopril ?P 0.05 Valsartan + Captopril vs. Captopril 0 0.5 1 1.5 2 2.5 3 3.5 % of Patients n = 201 154 23 253 90 46 34 VALIANT研究的意义 第一次证实ARB改善急性心梗患者生存率作用与已证实剂量ACEI相当 缬沙坦与证实剂量的卡托普